Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Stefan A. Koerber, Katharina Sprute, Clemens Kratochwil, Erik Winter, Matthias F. Haefner, Sonja Katayama, Ingmar Schlampp, Klaus Herfarth, Klaus Kopka, Ali Afshar-Oromieh, Stefanie Zschaebitz, Tim Holland-Letz (+6 others)
2020 European Journal of Nuclear Medicine and Molecular Imaging  
First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected
more » ... selected metastases. Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated. In total, 37% of the metastases were bone metastases, 48% were pelvic nodal metastases, and 15% were nodal metastases outside of the pelvis. After PSMA-guided radiotherapy, a biochemical response was detected in 83% of the cohort. A statistically significant decrease in the standard uptake value (SUV) was seen in irradiated metastases. After a median follow-up of 26 months, the 3-year OS and bPFS were 84% and 55%, respectively. The median time of ADT-free survival was 13.5 months. A better clinical outcome was observed for patients receiving concomitant ADT or more than 24 fractions of radiation. PSMA-guided radiotherapy is a promising therapeutic approach with excellent infield control for men with oligorecurrent prostate carcinoma. However, prospective, randomized trials are necessary to determine if this approach confers a survival advantage.
doi:10.1007/s00259-020-04777-z pmid:32405735 fatcat:lx7mc6r365fjzoqnj4mha4midm